Evidence map›Paper›PMID 34272720›Full record

ReviewHuman cell2021

Mesenchymal stem cells: ideal seeds for treating diseases.

Guanwen Gao, Chenyang Fan, Weiquan Li, Runzhang Liang, Chuzhong Wei, Xiaojie Chen, Yue Yang, Yueyuan Zhong, Yingqi Shao, Yi Kong and 2 more

Abstract readReview
In one paragraph

Review in Human cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Flavonoids ofPreventive nutrition and food science · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Guanwen Gao *School of Laboratory Medicine, The First Affiliated Hospital, Bengbu Medical College, Bengbu, China.
Chenyang Fan *Department of Clinical Medicine, Medicine and Technology School of Zunyi Medical University, Zunyi, China.
Weiquan LiClinical Research Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, China.
Runzhang LiangClinical Research Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, China.
Chuzhong WeiClinical Research Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, China.
Xiaojie ChenClinical Research Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, China.
Yue YangClinical Research Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, China.
Yueyuan ZhongClinical Research Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, China.
Yingqi ShaoClinical Research Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, China.
Yi KongClinical Research Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, China.
Zesong LiGuangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Department of Urology, Shenzhen Second People's Hospital (Shenzhen Institute of Translational Medicine), The First Affiliated Hospital of Shenzhen University, Shenzhen, China. lzssc@email.szu.edu.cn.
Xiao ZhuSchool of Laboratory Medicine, The First Affiliated Hospital, Bengbu Medical College, Bengbu, China. bioxzhu@yahoo.com.ORCID http://orcid.org/0000-0002-1737-3386

Funding

National Natural Science Foundation of China 81541153National Natural Science Foundation of China 81972366
6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs), a kind of multipotent stem cells with self-renewal ability and multi-differentiation ability, have become the "practical stem cells" for the treatment of diseases. MSCs have immunomodulatory properties and can be used to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and Crohn's disease. MSCs also can be used in cancer and aging. At present, many clinical experiments are using MSCs. MSCs can reduce the occurrence of inflammation and apoptosis of tissue cells, and promote the proliferation of endogenous tissue and organ cells, so as to achieve the effect of repairing tissue and organs. MSCs presumably also play an important role in Corona Virus Disease 2019 (COVID-19) infection.

Indexed as

Mesenchymal Stem CellsAnimalsApoptosisAutoimmune DiseasesCell- and Tissue-Based TherapyCell ProliferationCOVID-19Crohn DiseaseHumansImmunomodulationInflammationLupus Erythematosus, SystemicMesenchymal Stem Cell TransplantationMiceNeoplasmsAgingAutoimmune diseasesCancerCOVID-19InflammationMesenchymal stem cells

Identifiers

PMID34272720
PMCPMC8284686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.